Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes

Table 3

Changes in anthropometric and metabolic parameters in subgroups of obese hypogonadal men with type 2 diabetes and total testosterone <8 nmol/L versus total testosterone >8 nmol/L and <12 nmol/L after treatment with testosterone undecanoate for up to 6 years.

	T < 8 nmol/L (𝑛=53)	T > 8 nmol/L (𝑛=103)
Mean age (years)	61.43±7.78	60.96±5.24
Anthropometry
Decrease in weight (kg)	16.05±1.01	18.42±0.71
Weight reduction from baseline (%)	13.75±0.84	15.88±0.58
Decrease in BMI (kg/m^2)	5.06±0.32	5.94±0.22
Decrease in waist circumference (cm)	12.84±0.64	10.77±0.36
Diabetic parameters
Decrease in fasting glucose (mg/dL)	32.31±5.19	24.4±2.42
Decrease in HbA1c (%)	1.98±0.09	1.9±0.07
Other metabolic parameters
Decrease in total cholesterol (mg/dL)	94.99±8.72	106.21±4.04
Increase in HDL cholesterol (mg/dL)	14.87±3.08	10.78±1.3
Decrease in LDL cholesterol (mg/dL)	51.28±5.29	44.07±2.83
Decrease in triglycerides (mg/dL)	107.73±12.23	98.55±5.64
Decrease in systolic blood pressure (mmHg)	22.11±1.56	23.57±0.97
Decrease in diastolic blood pressure (mmHg)	9.21±1.41	18.29±0.88
Testosterone
Increase in testosterone (nmol/L)	11.45±0.54	6.37±0.37